Breakout Session 4: Track B

Optimizing Diagnostic and Prognostic Biomarkers of CASH using Machine Learning

> Dr. Diana Vera Cruz Bioinformatician, University of Chicago

Dr. Romuald Girard Assistant Professor, University of Chicago

Optimizing Diagnostic and Prognostic Biomarkers of CASH using Machine Learning

Optimizing and Sharing Data for Machine Learning [ML] Analyses of Multiomic Biomarkers of Cavernous Angiomas with Symptomatic Hemorrhage [CASH]






THE UN CH MED BIOL SCIE


Cavernous Angiomas (CAs) are fairly common cerebrovascular anomalies






VENOUS ANGIOMA


Venous developmental anomaly Regional venous dysmorphism





CAVERNOUS MALFORMATION Hemorrhagic proliferative dysangiogenesis







ARTERIOVENOUS MALFORMATION Arteriovenous shunting


Cerebral CAs behavior is unpredictable

- CAs are abnormal clusters of enlarged capillary vessels embedded in normal brain or spinal cord tissue
- 2 forms : sporadic/solitary or familial/multifocal
- CA without prior symptomatic hemorrhage (SH)
 Low initial risk of SH (0.4 to 2.4% per year)
- CA with recent SH
 - High risk of rebleeding after initial SH (AI-Shahi et al., 2012)
 - 10-fold increase
 - 3.8 to 29.5% per year

T₂-weighted MRI




in sporadic patient



in familial patient


A complex interplay of angiogenesis and inflammatory processes




4 categories of biomarkers defined by the FDA-NIH Biomarker Working Group

- A relevant biomarker may reflect <u>chronic disease</u> over the patient's lifetime, <u>recent</u> <u>acute clinical activity</u> or <u>predict future events</u> (Amur et al., 2015).
- 4 categories of biomarkers:
 - ✓ **Diagnostic** distinguish patients with a particular disease.
 - ✓ <u>Prognostic</u> provide information on the likely course of disease in an untreated individual.
 - Predictive provide a forecast of the potential responses (favorable or unfavorable) to one or more specific treatments.
 - ✓ <u>Response</u> are dynamic assessments of a biological response after a therapeutic intervention, include:
 - > **Safety** indicating biological adverse effects in response to treatment.
 - > Pharmacodynamic indicating the intended activity of the drug.
 - Efficacy-response or surrogate endpoints predicting a specific disease-related clinical outcome.

Plasma molecules effectively combine into a diagnostic and prognostic biomarker of hemorrhagic activity of CCM






Lyne et al., 2019

Girard et al., 2018

Methodology to Identify Candidate Biomarkers



Multi-Omic Datasets in Diagnostic and Prognostic Discovery Cohorts

	Assay	Diagnostic	Prognostic
Metabolites	LC-MS/MS	11	11
Proteins	ELISA	16	16
miRNA	ddPCR	5	-
Patients		20/20	15/15

Pilot cohorts: General Workflow

Cleaned and homogenized dataset


Data transformation and NA imputation

Correlation with CCM status and individual regressions


Feature selection: Elastic Net & Logistic models

Comparison across models based on subsets of the selected features

Pilot cohorts: General Workflow




Database structure



- Homogeneity across tables: Universal patient ID.
- Tidy format for data analysis and repository sharing.

Pilot cohorts: General Workflow



Data transformation

Test of normality (Shapiro-Wilk test)


- Metabolites: linear
- Proteins: log₂
- miRNA log₂

NA imputation

- Model-based imputation method
- Hot-Deck initialized

Individual logistic regression

Pilot cohorts: General Workflow



Feature selection

- Elastic Net optimized for accuracy and repeated k-fold cross-validation.
- Logistic regression over the complete set and conditional logistic regression to evaluate the performance of propensity-match.

Reduced models


• Subset combinations of n elements, arranged by highest AUC.


Best models criteria

• Highest AUCs for a given number of features and lowest number of unique molecule types.

Subset models - AUC Comparison

Total model considered: 9948 (Combinations from 1 to 6 elements max)






Subset models - AUC Comparison

Distribution of features per model Frequency in window 0.20 0.15 0.10 0.05 Feature Number of models 10 20 30 40 50 83.75 83.5 83.25 83.25 83 84.75 84.5 84.25 81.25 80.5 79.25 78.75 78.75 78.75 78.21 77.75 76.75 76.75 76.75 76.75 75.75 75.75 74.5 73.5 73.5 73.5 72.5 72.5 72.5 72.5 72.5 72.5 72.5 76.75 75 75.55 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 77.75 77.75 77.75 77.75 77.75 77.75 77.75 77.75 77.75 77.75 77.75 76.75 77.75 76.75 77.75 77.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 76.75 77.75 76.75 76.75 76.75 76.75 76.75 77.75 77.75 76.75 76.75 77.75 76.75 77.75 77.75 76.75 77.75 77.75 76.75 77.75 77.75 76.75 76.75 77 80.25 88.1 87.25 86.75 86.75 85.75 85.75 82.7 82. 82.2 81 80. 81 Metric at end of window

Distribution of the number of features per model



Future work and Perspective

- Identification of the best diagnostic and prognostic models.
- Best models evaluation in testing cohorts: n > 260 patients.
- Model performance in relation of the known confounders of CCM clinical activity (e.g., CCM phenotype, lesion localization, gender and age).